

AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claims 1-286 (canceled)

287. (previously presented) A method of inducing tumor tissue regression in a patient comprising administering to said patient a therapeutically effective amount of an antibody immunospecific for $\alpha_v\beta_3$.

288. (previously presented) The method of claim 287 wherein said antibody is a monoclonal antibody.

289. (previously presented) The method of claim 287 or 288 wherein said tissue is a solid tumor tissue.

290. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is bladder.

291. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is breast.

292. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is colon.

293. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is lung.

294. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is skin.

295. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is a carcinoma.

296. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is a melanoma.

297. (previously presented) The method of claim 287 or 288 wherein said administering comprises intravenous administration.

298. (previously presented) The method of claim 287 or 288 wherein said administering comprises oral administration.

299. (previously presented) The method of claim 287 or 288 wherein said administering comprises transdermal administration.

300. (previously presented) The method of claim 287 or 288 wherein said administering comprises intramuscular administration.

301. (previously presented) The method of claim 287 or 288 wherein said administering comprises subcutaneous administration.
302. (previously presented) The method of claim 287 or 288 wherein said administering comprises intracavity administration.
303. (previously presented) The method of claim 287 or 288 wherein said administering comprises peristaltic administration.
304. (previously presented) The method of claim 287 or 288 wherein said administering comprises parenteral administration.
305. (previously presented) The method of claim 287 or 288 wherein said administering comprises systemic administration.
306. (previously presented) The method of claim 287 or 288 wherein said administering comprises administration by gradual infusion.
307. (previously presented) The method of claim 287 or 288 wherein said administering comprises one or more dose administrations daily, for one or several days.
308. (previously presented) The method of claim 287 or 288 wherein said administering comprises a single dose.
309. (previously presented) The method of claim 287 or 288 wherein said amount is from about 0.1 mg/kg to about 300 mg/kg patient body weight.
310. (previously presented) The method of claim 287 or 288 wherein said amount is from about 0.2 mg/kg to about 200 mg/kg patient body weight.
311. (previously presented) The method of claim 287 or 288 wherein said amount is from about 0.5 mg/kg to about 20 mg/kg patient body weight.
312. (previously presented) The method of claim 287 or 288 wherein said administering is conducted in conjunction with chemotherapy.
313. (previously presented) The method of claim 287 or 288 wherein the patient is human.
314. (previously presented) The method of claim 287 or 288 wherein the patient is a patient with angiofibromas.
315. (previously presented) The method of claim 287 or 288 wherein the patient is a patient with retrolental fibroplasia.
316. (previously presented) The method of claim 287 or 288 wherein the patient is a patient with hemangiomas.
317. (previously presented) The method of claim 287 or 288 wherein the patient is a patient with Kaposi sarcoma.

318. (previously presented) The method of claim 287 or 288 wherein said antibody preferentially inhibits fibrinogen binding to $\alpha_v\beta_3$ compared to fibrinogen binding to $\alpha_{IIb}\beta_3$.
319. (previously presented) The method of claim 287 or 288 wherein said antibody specifically binds $\alpha_v\beta_3$ complex.
320. (previously presented) The method of claim 287 or 288 wherein said antibody is an antibody fragment.
321. (previously presented) The method of claim 320 wherein said antibody is a Fab fragment.
322. (previously presented) The method of claim 320 wherein said antibody is a Fab' fragment.
323. (previously presented) The method of claim 320 wherein said antibody is a F(ab')₂ fragment.
324. (previously presented) The method of claim 320 wherein said antibody is a F(v) fragment.
325. (previously presented) The method of claim 288 wherein said monoclonal antibody has the binding specificity of the monoclonal antibody LM609 having ATCC accession number HB 9537.
326. (previously presented) The method of claim 288 wherein said monoclonal antibody is humanized.
327. (previously presented) The method of claim 287 or 288 wherein said tumor tissue is metastatic.
328. (previously presented) The method of claim 287 or 288 wherein said antibody is administered in a composition.
329. (previously presented) The method of claim 328 wherein said composition is a sterile pharmaceutical composition.
330. (previously presented) The method of claim 287 or 288 wherein said administering is conducted following surgery.
331. (previously presented) The method of claim 287 or 288 wherein said patient was previously treated for a first tumor.
332. (previously presented) The method of claim 331 wherein said first tumor is a solid tumor.
333. (previously presented) The method of claim 331 wherein said first tumor is a carcinoma.
334. (previously presented) The method of claim 331 wherein said first tumor is a melanoma.

335. (previously presented) The method of claim 331 wherein said patient previously underwent surgery to remove said first tumor.
336. (previously presented) The method of claim 331 wherein said patient was previously treated with chemotherapy.
337. (previously presented) A method of inducing solid tumor tissue regression in a human patient in need thereof, said method comprising administering to said human patient a therapeutically effective amount of a humanized monoclonal antibody immunospecific for $\alpha_v\beta_3$ complex.
338. (previously presented) The method of claim 337 wherein said humanized monoclonal antibody has the binding specificity of the monoclonal antibody LM609 having ATCC accession number HB9537.
339. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a melanoma.
340. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a carcinoma.
341. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a skin carcinoma solid tissue tumor.
342. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a bladder carcinoma solid tissue tumor.
343. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a breast carcinoma solid tissue tumor.
344. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a colon carcinoma solid tissue tumor.
345. (previously presented) The method of claim 337 or 338 wherein said tumor tissue is a lung carcinoma solid tissue tumor.
346. (new) The method of claim 287, 288 or 337 wherein said antibody preferentially binds $\alpha_v\beta_3$ over other integrins.
347. (new) The method of claim 287, 288 or 337 wherein said antibody does not immunoreact with a β_3 subunit.
348. (new) The method of claim 287, 288 or 337 wherein said antibody does not immunoreact with an α_v subunit.
349. (new) The method of claim 287, 288 or 337 wherein said antibody does not immunoreact with integrins other than $\alpha_v\beta_3$.